Cardiovascular Research With C. Michael Gibson, MD


Dr. C. Michael Gibson is an interventional cardiologist, cardiovascular researcher, and educator who pioneered our understanding of the open artery and the open microvasculature hypothesis in the setting of heart attack. He is also CEO of the combined not-for-profit Baim and PERFUSE research institutes at Harvard Medical School.

Pulmonary Embolism: A Morbid Condition With Emerging Treatment Options

Dear readers,

Here are my picks for the week.

The NEJM has an excellent review article on pulmonary embolism, which remains a morbid condition with new and emerging treatment options. An article in Circulation shows that we may need bigger final lumens in the left main following PCI to reduce adverse events. Another article in Circulation highlights the newest data from multivessel PCI in AMI. Tricuspid regurgitation (TR) and HFpEF often run together, and a third excellent Circulation article highlights what to expect with treatment of the TR. Finally, an article in JACC covers when we should not use DOACs!

Kind regards,
C. Michael Gibson, MD